We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-14.95%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.72B
AUM Growth
-$950M
Cap. Flow
-$368M
Cap. Flow %
-21.39%
Top 10 Hldgs %
48.56%
Holding
373
New
67
Increased
88
Reduced
111
Closed
78

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$59.4M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$32.9M
3
AMGN icon
Amgen
AMGN
+$18M
4
LLY icon
Eli Lilly
LLY
+$15.9M
5
BMY icon
Bristol-Myers Squibb
BMY
+$7.23M

Top Sells

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$6.04M
2
ABT icon
Abbott
ABT
+$4.77M
3
RGNX icon
Regenxbio
RGNX
+$4.1M
4
CELG
Celgene Corp
CELG
+$3.94M
5
UTHR icon
United Therapeutics
UTHR
+$3.59M

Sector Composition

Rank Sector Weight
1 Healthcare 17.88%
2 Financials 0.23%
3 Consumer Staples 0.05%
4 Technology 0.03%
5 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZGNX
26
CALL
DELISTED
Zogenix, Inc.
ZGNX
$15M 0.87%
12,366
+11,138
+907% +$122K
CLVS
27
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
$15M 0.87%
3,378
-2,472
-42% -$87K
ABBV icon
28
CALL
AbbVie
ABBV
$465B
$13.8M 0.8%
2,204
-1,932
-47% -$118K
ACOR
29
PUT
DELISTED
Acorda Therapeutics
ACOR
$11.6M 0.67%
51
+46
+920% +$109K
HZNP
30
CALL
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$9.65M 0.56%
5,962
+1,874
+46% +$34K
ALKS icon
31
CALL
Alkermes
ALKS
$8.47B
$9.11M 0.53%
1,639
-1,610
-50% -$86.1K
TVTX icon
32
CALL
Travere Therapeutics
TVTX
$5.2B
$9.08M 0.53%
4,798
-1,495
-24% -$30.6K
ESRX
33
PUT
DELISTED
Express Scripts Holding Company
ESRX
$8.19M 0.48%
1,191
-500
-30% -$35.8K
EXEL icon
34
PUT
Exelixis
EXEL
$14.2B
$8.04M 0.47%
5,392
– –
VRTX icon
35
CALL
Vertex Pharmaceuticals
VRTX
$124B
$7.88M 0.46%
1,070
-885
-45% -$72K
ALNY icon
36
PUT
Alnylam Pharmaceuticals
ALNY
$38.5B
$7.7M 0.45%
2,056
+1,187
+137% +$49.7K
TSRO
37
PUT
DELISTED
TESARO, Inc.
TSRO
$7.57M 0.44%
563
+513
+1,026% +$64.7K
REGN icon
38
CALL
Regeneron Pharmaceuticals
REGN
$72.9B
$7.42M 0.43%
202
+139
+221% +$52.9K
ABBV icon
39
PUT
AbbVie
ABBV
$465B
$7.38M 0.43%
1,178
– –
SIOX
40
CALL
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$7.11M 0.41%
716
+131
+22% +$13.8K
OTLK icon
41
Outlook Therapeutics
OTLK
$169M
$6.74M 0.39%
13,990
-189
-1% -$106K
PBYI icon
42
CALL
Puma Biotechnology
PBYI
$406M
$6.68M 0.39%
2,177
+156
+8% +$6.75K
PTCT icon
43
CALL
PTC Therapeutics
PTCT
$6.25B
$6.48M 0.38%
5,940
+1,951
+49% +$20.5K
HUM icon
44
CALL
Humana
HUM
$46.7B
$5.94M 0.35%
291
+13
+5% +$2.48K
BIIB icon
45
Biogen
BIIB
$30.4B
$5.67M 0.33%
+20,000
New +$5.93M
HES
46
CALL
DELISTED
Hess
HES
$5.62M 0.33%
902
-1,157
-56% -$63.2K
KITE
47
CALL
DELISTED
Kite Pharma, Inc.
KITE
$5.25M 0.31%
1,171
+89
+8% +$4.37K
PBYI icon
48
PUT
Puma Biotechnology
PBYI
$406M
$5.22M 0.3%
1,699
+1,056
+164% +$45.7K
MTFB
49
DELISTED
Motif Bio plc ADRs
MTFB
$5.12M 0.3%
+847,826
New +$4.93M
FOLD
50
CALL
DELISTED
Amicus Therapeutics
FOLD
$5.08M 0.3%
10,216
+584
+6% +$4.04K
1
2
3 4 5

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q4 2016 Portfolio in Review

As of Q4 2016, Sabby Management held 373 positions worth $1.72B, down 36% from $2.67B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Sabby Management withdrew a net $368M in Q4 2016, closing 78 positions and reducing 111 holdings. Its most notable exit was Shire pic, an estimated $6.04M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 9.2% a quarter earlier, followed by Financials and Consumer Staples.

Against the trend, Sabby Management opened a new position in Eli Lilly worth $15.7M.

  • Sabby Management's largest Q4 2016 buy was Eli Lilly: 213,113 shares worth $15.7M.
  • Sabby Management added most to Sarepta Therapeutics in Q4 2016, an estimated $59.4M increase.
  • Sabby Management's biggest Q4 2016 reduction was Regenxbio, cutting an estimated $4.1M.
  • Sabby Management fully exited Shire pic in Q4 2016, selling an estimated $6.04M.
  • Sabby Management's ten largest holdings make up 49% of its $1.72B portfolio in Q4 2016.
  • Sabby Management opened 67 new positions and closed 78 in Q4 2016.
  • Sabby Management's portfolio value fell 36% quarter-over-quarter to $1.72B.

Based on Sabby Management's 13F filing for Q4 2016, filed 14 Feb 2017.